• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Exelixis

Exelixis

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Ipsen Reports Strong First Quarter 2017 Sales Growth of 19,1%1

    Ipsen Reports Strong First Quarter 2017 Sales Growth of 19,1%1

  2. Global Hepatocellular Carcinoma (Nexavar & Miripla) Drug Sales 2017 - Pipeline Analysis and Market Forecast 2022 - Research and Markets

    Global Hepatocellular Carcinoma (Nexavar & Miripla) Drug Sales 2017 - Pipeline Analysis and Market Forecast 2022 - Research and Markets

  3. Is This the Year Exelixis Excels?

    The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.

  4. Don't Bail on Biotech

    We see opportunity as fleeing investors trigger an irrational sell-off.

  5. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  6. Beware 5-Star Stocks Bearing No Moats

    Lack of competitive advantages may mean these companies aren't the bargains they seem to be.

  7. Biotech ETFs: Which One Is Best Now?

    The five biotech ETFs have very different portfolios with markedly different performance.

©2017 Morningstar Advisor. All right reserved.